iMALDI

Immuno MALDI (iMALDI) derives from a mass spectrometric and immunoaffinity-based peptide chip technology developed in Dr. Borchers’ laboratory. Conventional sample preparation for MS protein analysis can be labor intensive and time consuming, especially if low-abundance proteins need to be detected and quantitated. However, iMALDI is a rapid method involving the use of antibodies to capture specific peptides and thus is well-suited for the quantitation of low-abundance proteins. These antibodies, which are bound to small beads for easy manipulation, can be deposited in rows on the surface of a small piece of glass or plastic to form a diagnostic "chip". The Centre offers iMALDI for fee-for-service or in collaboration through the development and implementation of specific iMALDI assays.
The Centre’s goals are to further develop, improve, multiplex, and automate the iMALDI technique; making iMALDI applicable for use in diagnostic clinics and research laboratories. By developing and improving reagents, protocols, robotic systems, and software, the entire iMALDI technology will be automated into a user-friendly diagnostics platform. All steps in the iMALDI process (i.e., sample preparation, chip fabrication, MS analysis, and data interpretation) will be integrated into a safe, efficient, and easy-to-use “candidate product” for the analysis of multiple proteins. For the development and commercialization of iMALDI, we have assembled a team from academia, clinical, environmental and research organizations, and industry, providing expertise in clinical diagnostics, ecology, environmental assessment, mass spectrometry, protein chemistry, immunology, robotics, engineering, software development and business. The ultimate goal of this interdisciplinary team is to provide the community with a robust, cost-effective, safe, and easy-to-use diagnostic device for absolute quantitation of the expression and modification levels of multiple proteins in a rapid and simultaneous manner, with the accuracy and specificity required for clinical, biological, and ecological samples.

Selected iMALDI Publications
  1. Reid, J.D., Holmes, D.T., Mason, D.R., Shah, B., Borchers, C.H. Towards the Development of an Immuno MALDI (iMALDI) Mass Spectrometry Assay for the Diagnosis of Hypertension
    JASMS, (2010)
  2. Jiang, J., Parker, C.E., Fuller, J.R., Kawula, T.H., Borchers C.H., An immunoaffinity tandem mass spectrometry (iMALDI) assay for detection of Francisella tularensis. Analytica Chimica Acta. 605: 70 -79 (2007).
  3. Jiang, J., Parker C.E., Hoadley, K.A., Perou, C.M., Borchers C.H., Development of an Immuno Tandem Mass Spectrometry (iMALDI) Assay for EGFR Diagnosis. Proteomics Clin. Appl. 1: 1651 - 1659 (2007).
  4. Reid, J.D., Parker, C.E., Borchers C.H., Protein arrays for biomarker discovery. Current Opinion in Molecular Therapeutics. 9: 222-230 (2007).
  5. Jiang, J., Parker, C.E., Robinette, D., Borchers C.H., A Clinical Diagnostics Platform – Protein Detection Using an Immunoaffinity-based Peptide Chip. BIOforum Europe. 10/2006: 18-20 (2006).
  6. Warren, E.N., Jiang, J., Parker, C.E., Borchers C.H., Absolute Quantitation of Cancer-related Proteins using an MS-based Peptide Chip. BioTechniques. 38: S7-S11 (2005).
  7. Warren, E.N., Elms, P.J., Parker, C.E, Borchers C.H., Development of a Protein Chip: A MS-based Method for Quantitation of Protein Expression and Modification Levels using an Immunoaffinity Approach. Analytical Chemistry. 76: 4082-4092 (2004)